Abstract
In 2014, the USPTF recommended that women with two moderate risk factors for preeclampsia be considered for low dose aspirin (LDA) therapy to prevent preeclampsia but stated that “the evidence was less certain for this approach”. In 2020, the ASPIRIN trial showed that LDA decreased the rate of preeclampsia as well as preterm birth (PTB) in nulliparous women. We sought to determine if women with an additional risk factor beyond being nulliparous differentially benefitted from LDA for preventing PTB and hypertensive disorders of pregnancy (HDP) compared to women who did not have a second risk factor.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
